Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 9/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5408810 | 0.98 | TAAR1 (0.46) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL3676582 | 0.80 | TAAR1 (0.52) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL30788816 | 0.76 | ALDH1A1 (0.46) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL4982671 | 0.76 | TSHR (0.46) | TSHRALDH1A1KIF11KCNN4CA1 | |
| SCHEMBL11601071 | 0.76 | TSHR (0.46) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL506977 | 0.75 | TAAR1 (0.52) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL10749002 | 0.75 | TAAR1 (0.52) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| Hydrochloric Acid SCHEMBL9280100 | 0.73 | TAAR1 (0.50) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL9289093 | 0.73 | TAAR1 (0.50) | TAAR1TSHRALDH1A1KIF11KCNN4 | |
| SCHEMBL6680835 | 0.73 | ALDH1A1 (0.42) | TSHRALDH1A1KIF11CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1558250-A4 | GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050261325-A1 | Especially N-(3-carbonylamino3-substituted-propyl)spiro(indene- or indane-2,4'-piperidine derivatives, useful in treatment of inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, autoimmune disorders and atherosclerosis | MERCK SHARP & DOHME CORP. | 2005-11-24 | — | — | US | disclosed |
| EP-1558250-A1 | GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041279-A1 | GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261325-A1 | Especially N-(3-carbonylamino3-substituted-propyl)spiro(indene- or indane-2,4'-piperidine derivatives, useful in treatment of inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, autoimmune disorders and atherosclerosis | CCR1, CCR3, CCR2 | TAAR1 121/4885TSHR 655/4885ALDH1A1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.